FDA Names First Five Devices for READI-Home Readmission Challenge

The US Food and Drug Administration has selected the first five devices for its READI-Home Innovation Challenge, a program built to cut hospital readmissions by speeding patient access to home-based medical technologies following an acute hospital stay.

The initial cohort, announced under the program's full name — Reducing Readmissions through Device Innovation for the Home — includes two devices with direct applications in sleep medicine, one from Epitel and one from Prapela, alongside technologies from Becton Dickinson, Current Health Limited, and Skribe Medical.

Avoidable readmissions create significant logistical and financial challenges for hospitals, and the FDA has framed the challenge as a mechanism to prevent them by moving monitoring and diagnostics into patients' homes.

Which sleep devices made the cut?

Epitel's REMI Neuro Monitoring Home Health Hub is a wireless wearable electroencephalography (EEG) system designed for extended-duration monitoring. Applied at the point of hospital discharge, it is intended for use in home and ambulatory environments by individuals aged six and older. Its target indications include assessment for potential seizures, poor sleep, and delirium — conditions that typically require in-clinic EEG infrastructure to evaluate.

"We are incredibly honored that the FDA has selected REMI as one of the inaugural technologies for the READI-Home Innovation Challenge," Mark Lehmkuhle, chief technology officer at Epitel, said in a release. "Our mission has always been to make brain health monitoring more accessible and comfortable. Working directly with the FDA allows us to rapidly adapt neuro-monitoring for home environments, helping support post-discharge patients and easing pressure on overloaded health systems."

The second sleep-related selection, the Prapela Therapeutic Vibrational Crib Mattress, targets a specific pediatric population: infants with single-ventricle heart disease. The mattress contains a miniaturized vibrating actuator that delivers low-amplitude mechanical vibration during infant sleep. Its stated aim is to reduce the frequency, duration, and severity of hypoxemic and bradycardic episodes in this patient group.

What else did the FDA select?

Three additional devices advanced to the interaction phase:

• BD Self-Collection Kit: a home self-collection blood sampling kit designed by Becton, Dickinson and Company.
• CRS Solution: an artificial intelligence-based software medical device from Current Health Limited for early identification of patients at risk of developing cytokine release syndrome.
• Aurora System: a wearable, multi-sensor adhesive patch by Skribe Medical designed to non-invasively estimate left ventricular ejection fraction.

What does the interaction phase involve?

Selected participants enter a structured engagement process with the FDA rather than proceeding through standard review alone. The interaction phase provides early engagement with agency reviewers and rapid feedback intended to help manufacturers refine device design and testing for home-use indications.

For R&D managers at the selected companies, the practical value is regulatory de-risking: direct FDA dialogue during design iteration, before submission, on questions specific to home environments — usability by non-professional caregivers, durability outside clinical settings, and interpretation of extended-duration data.

All performance claims for the selected devices — from REMI's seizure and delirium assessment capability to the Prapela mattress's effect on hypoxemic and bradycardic episodes — remain vendor statements at this stage; the challenge announcement covers selection, not clearance or clinical validation outcomes. The FDA has not published a timeline for the interaction phase or for subsequent phases of the program.

The agency has also not said whether further selection rounds will follow, leaving open the question of whether the inaugural cohort of five sets the scale for the challenge or marks the first of multiple intakes.